Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. (ENSC) filed an 8-K (Item 3.01) reporting that Nasdaq’s listing qualifications staff sent a Deficiency Letter saying the company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price for its common stock has been below $1.00 for 30 consecutive business days. Under Nasdaq rule 5810(c)(3)(A), Ensysce has 180 calendar days — until August 24, 2026 — to regain compliance by having its stock close at $1.00 or higher for at least ten consecutive business days.

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) (minimum $1.00 bid price); notice issued under rule 5810(c)(3)(A).
• Compliance period: 180 days, ending August 24, 2026. Requirement: $1.00+ closing bid for at least 10 consecutive business days.
• Possible follow-up: Nasdaq may grant a second 180-day cure period if Ensysce meets all other listing standards; Nasdaq could delist if it determines the company cannot cure.
• Trading status: The Deficiency Letter does not affect current listing — ENSC continues to trade on the Nasdaq Capital Market under the symbol “ENSC.”

Why It Matters
A continued failure to meet the $1.00 minimum bid price could lead to delisting from Nasdaq. Delisting can reduce liquidity, make it harder to buy or sell shares, limit access to public capital, and potentially lower the market value of the stock. Ensysce says it will monitor the share price and evaluate options to regain compliance, but there is no assurance that remedies, additional time, or any appeal would be successful.